IceCure Medical Q3 Earnings Call Highlights

IceCure Medical (NASDAQ:ICCM) reported a 26% increase in revenue for the first nine months of 2026, driven by an 83% rise in U.S. sales of its ProSense cryoablation system. The company’s losses widened as it spent more on clinical research and its commercial expansion.

Revenue rose to $2.6 million from $2.1 million in the same period a year earlier, while net loss increased to approximately $12.9 million from $10.8 million, Chief Financial Officer Meir Peleg said on the company’s November 18 earnings call.

CEO Eyal Shamir said IceCure had expanded its U.S. commercial footprint to 21 states by the end of the third quarter, up from 11 states at the end of the second quarter of 2025. The company added sales and marketing professionals in regions including New York, Southern California, the Midwest and Florida, as well as clinical support staff.

Spending rises alongside revenue

Gross profit for the nine months ended September 30 increased approximately 22% to $762,000 from $626,000, Peleg said. Research and development expenses rose to approximately $6.5 million from $5.1 million, primarily because of higher spending on the ChoICE post-marketing study and other clinical and development activities.

Sales and marketing expenses increased about 20% to $3.6 million, reflecting the expansion of U.S. commercial activities. General and administrative expenses rose to approximately $3.5 million from $3.3 million.

IceCure ended September with approximately $8.2 million in cash and cash equivalents, compared with $8.9 million at the end of 2025.

Asked about the revenue outlook, Peleg said the company was not providing guidance but projected “healthy double-digit growth” in 2027. He also said IceCure expected fourth-quarter 2026 revenue to exceed third-quarter revenue, while noting that he could not say whether it would match the prior year’s fourth-quarter performance.

Shad Good, vice president of sales for North America, said the company expected U.S. sales revenue to continue increasing quarter over quarter.

ChoICE study enrollment timeline uncertain

Shamir said IceCure had established three ChoICE clinical sites and begun enrolling and treating patients at participating U.S. centers. During the question-and-answer session, Good said the study had four sites as of the call and that the company expected to finalize additional sites in the near future.

Shamir said it was too early to determine whether the company could meet a previously discussed target of 400 patients within three years. Some site contracts and agreements were taking longer than expected, he said, although he added that prospective sites had patient pipelines and that some could begin treating patients before year-end or early in 2027.

Asked about the possibility of an extension, Shamir said IceCure was in continuous communication with the U.S. Food and Drug Administration and would discuss the matter with the agency.

IceCure did not provide an updated U.S. installed base of ProSense consoles. Shamir said the company had orders to ship before year-end and expected to provide updated information in the coming weeks or months.

International expansion

Shamir said recent international developments included regulatory approval in China and an exclusive distribution agreement in the Netherlands. IceCure was discussing a distribution-based arrangement with potential partners in China, he said, without providing a timeline for revenue there.

The company was awaiting Health Canada approval for a breast cancer indication and expected a decision in the next few months, Shamir said. In Japan, he said IceCure expected Terumo to submit an application to the country’s Pharmaceuticals and Medical Devices Agency during the first half of 2027.

About IceCure Medical (NASDAQ:ICCM)

IceCure Medical Ltd. is an Israel-based medical technology company that develops and commercializes minimally invasive cryoablation systems. Its technology uses liquid nitrogen to freeze and destroy targeted tissue, offering a percutaneous approach to treating tumors. The company’s ProSense system is designed for image-guided cryoablation and is used in procedures involving breast, kidney, lung, bone and other tumors. IceCure also offers the IceSense3 system for treating benign breast fibroadenomas.